Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... HCC. Our HEAT trial has been designed to evaluate the efficacy of ThermoDox in combination with RFA to improve patient outcomes for this cost effective, minimally invasive ... are few non-surgical therapeutic treatment options available as radiation therapy and chemotherapy are largely ineffective in the treatment of primary liver cancer. About ThermoDox ...
2009 NOV 23 ... trials supported by this grant will focus on evaluating innovative single agent and combination studies of pralatrexate in Burkitt's lymphoma, multiple myeloma, specific indolent ... work will ultimately benefit patients with cancer." Pralatrexate is a chemotherapy drug classified as an antifolate that works by interfering with the ability of cancer ...
2009 NOV 23 ... an urgent need for better treatments. We investigated GBM cell killing by a novel drug combination involving DT-EGF, an Epidermal Growth Factor Receptor-targeted bacterial toxin, and ... for Glioblastoma multi-forme (GBM) involve surgery, radiotherapy, and cytotoxic chemotherapy; however, these treatments are not effective and there is an urgent need for better ...
2009 NOV 23 ... to analyze tissues harvested at primary debulking surgery before the initiation of combination chemotherapy in order to identify potential naive or intrinsic chemotherapy response proteins in ...
2009 NOV 23 ... patient was unable to tolerate, based on preclinical data suggesting efficacy of this combination," wrote R. Deboer and colleagues, Northwestern University, Medical Department. ... residual tumor that persisted despite radiation therapy (RT) and two cycles of cytotoxic chemotherapy. Vorinostat and retinoic acid were chosen as an alternative to cytotoxic chemotherapy, ...
2009 NOV 23 ... procedures," said Ramakrishnan. About Theragnostics: A theragnostic test can be a combination of molecular (or physiological) tests used to either select a patient for a particular ... patient samples from B-NHL patients who were treated with rituximab as a monotherapy (no chemotherapy or radiation therapy involved) and followed for over 10 years. According to this study, ...
2009 NOV 23 ... Adjuvant therapy extends disease-free survival in Stage III patients Combination chemotherapy is the standard of care in metastatic disease Avastin is used predominantly ...
2009 NOV 23 ... cancer patients who had SLNB after prior neoadjuvant chemotherapy was performed. A combination of radiopharmaceutical 99mTc-albumin colloid (Pharmalucence, MA, USA) and Patent Blue V ...
2009 NOV 23 ... stem cells. Here, we show that treating trastuzumab-resistant cancer cells with a combination of MUC1* antagonists and trastuzumab, reverses the drug resistance. Further, ... cells that had acquired Herceptin resistance had also acquired resistance to standard chemotherapy agents like Taxol, Doxorubicin, and Cyclophosphamide," wrote S.P. Fessler and ...
2009 NOV 23 ... M tegafur-0.4 M gimestat-1 M otastat potassium) monotherapy in 32 patients and S-1-based combination therapy in 5. The median number of administered courses of paclitaxel was 3.5 (1-14). ... A report, 'Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients ...
2009 NOV 23 ... that patients in good clinical condition are candidates for aggressive treatment with a combination of PTBD with metallic stent placement and chemotherapy." Migita and ...
2009 NOV 23 ... and 75.0% to 100.0% when compared with medical charts. The sensitivities using a combination of 3 data sources were 88.6% (95% confidence intervals: 85.7-91.1) compared with tumor ... According to a study from the United States, "Chemotherapy data are important to almost any study on cancer prognosis and outcomes. However, ...
2009 NOV 23 ... transcriptome, the phosphorylation status of EGFR pathway signaling targets, or a combination of both data sets. We observed that models derived from microarray gene expression data ... for prediction of lapatinib sensitivity in bladder cancer,' have been published. "Chemotherapy for metastatic bladder cancer is rarely curative. The recently developed small molecule, ...
2009 NOV 23 ... later, staging positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in combination with computed tomography identified an isolated left renal lymph node metastasis. The ... the tumor cells as metastases of an occult cervical cancer. Primary platin-based chemotherapy combined with paclitaxel leads to a complete apparative remission. Twelve months later, ...
2009 NOV 23 ... was negative; therefore, the cyclophosphamide, vincristine, and dacarbazine (CVD) combination chemotherapy was initiated. The combination chemotherapy was very ...
2009 NOV 16 ... primary surgery for their cancer, is Trastuzumab (Herceptin)--typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center ...
2009 NOV 16 ... with previously untreated or relapsed/refractory chronic lymphocytic leukaemia (CLL) in combination with chemotherapy • For the treatment of previously ...
2009 NOV 16 ... to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML. "This designation recognizes ...
2009 NOV 16 ... of Pediatric Infectious Diseases. In laboratory testing, the triple combination of oseltamivir (Tamiflu), amantadine (Symmetrel) and ribavirin showed a significant ... his data in September at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy held in San Francisco. The triple-combo testing is led by Adamas Pharmaceuticals, Inc. ...
2009 NOV 16 ... doses of oblimersen (3, 5 or 7 mg/kg/day) as continuous infusion on days 1-7 in combination with standard-dose docetaxel (Taxotere), Adriamycin and cyclophosphamide (TAC) on day 5 ... report 'Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer.' According to recent research from Germany, ...
